Dissecting mechanisms underlying benefits of selective TNF or ET-1 blockade in distinct demyelinating models thus shows promise to improve strategies promoting OPC differentiation following established demyelination and combat P-MS. Here, EDN1 is linked to myeloid sarcoma.